Alpha Cognition Inc ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

NDAQ:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by partystockeron Dec 22, 2021 3:14pm

128 Views

Post# 34255734

$ACOG pre-clinical results

Alpha Cognition delivered promising pre-clinical results for its ALPHA-1062 therapeutics earlier this month.

Administration of the drug proved to reduce the extent of the functional deficit of TBI and improved functional recovery compared to untreated subjects. The preclinical results, combined with clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI.

Shares went on a considerable 40% run after this news, but have settled back down towards a historical support zone around $.92. The fact prices reacted so positively to this news has me watching for continued announcements from $ACOG regarding their studies/testing to provide further catalysts.